Market Overview

UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility

Share:
Related ALKS
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying
Alkermes Gets FDA Nod for Two Month Dose of Aristada

Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS) with an Equal-weight rating and a $21 price target.

Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the stock valuation appropriately discounts growth outlook … ALKS trades at EV/EBITDA of 21x F13E and 15x F16E (we are focused on F16 because key launches are expected by then). We project 8-yr CAGR (F13-F21E) revenue growth of 6% and EPS growth of 13%. Note ALKS's low tax rate (est. mid-teens long-term) helps justify above average EBITDA multiple."

Alkermes closed at $19.97 on Monday.

Latest Ratings for ALKS

DateFirmActionFromTo
Jun 2017Leerink SwannDowngradesOutperformMarket Perform
Dec 2016Cantor FitzgeraldInitiates Coverage OnNeutral
Oct 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ALKS)

View Comments and Join the Discussion!